



Irish Platform for Patient Organisations, Science and Industry (IPPOSI), Rare Diseases Ireland (RDI) and UCAN Ireland welcome today's announcement from Minister for Health, Jennifer Carroll MacNeill TD, on the successful conclusion of two new Framework Agreements with the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland (MFI) on the pricing and supply of medicines.

These agreements represent an important step forward toward a more timely, transparent, and patient-centred medicines access system in Ireland. For too long, patients and families have experienced prolonged delays, huge unpredictability, and uncertainty while waiting for access to innovative and often life-changing treatments.

The commitment to delivering HSE reimbursement decisions within the 180-day timeline set by the Oireachtas in the Health Act 2013 is significant and represents meaningful progress toward addressing longstanding concerns around delays in access.

A reliable, time-bound reimbursement process is essential for improving patient access and outcomes.

We welcome reference to the establishment of a strategic partnership on the development of an early access programme and would encourage that these important discussions include both the clinical and the patient voice. With predictable timelines in place, it now becomes possible to credibly bridge access gaps ensuring patients are not left without options while decisions are being made.

The aim to make submissions for reimbursement within 6 months of EMA approval is another important step to ensure timely access for Irish patients.

We recognise the State's intention to secure better value through the increased use of generics and off-patent medicines. When implemented effectively, this approach can support the sustainability of the medicines budget and help create headroom for investment in innovation where unmet need remains.

Today's announcement marks an important milestone in the broader reform many of us have long called for. As patient-led organisations representing diverse communities across the health system, we have consistently highlighted the need for

a reimbursement pathway that is transparent, predictable, and supportive of patients at every stage.

We look forward to continued engagement with all partners to ensure that these commitments translate into real, tangible improvements - delivering timely, equitable access to medicines and strengthening Ireland's position as a country that both prioritises patient outcomes and supports life-changing health innovation.

To read the full press release from the Department of Health, please click [here](#).